Silvia Fernández Álvarez

Silvia Fernández Álvarez

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2026 in Cells
Verified
Journal Article
Open access
PDF file
IBIsabel María Vallejo Bermúdez
Isabel María Vallejo Bermúdez
Mabel Rocio Miranda EchagüeMabel Rocio Miranda Echagüe
Mabel Rocio Miranda Echagüe
SÁSilvia Fernández Álvarez
Silvia Fernández Álvarez
EAEster Irene Reina Alfonso
Ester Irene Reina Alfonso
LBLaura Blanca-Pariente
Laura Blanca-Pariente
Alejandra PeraAlejandra Pera
Alejandra Pera
CD57-expressing lymphocytes constitute a distinct subset of immune cells with enhanced cytotoxic and pro-inflammatory functions. Initially described in the context of chronic viral infections, most notably cytomegalovirus (CMV), these cells are now recognized as central contributors to immunosenescence and age-related immune dysregulation. Their progressive accumulation reflects prolonged antigenic exposure and sustained immune activation, thereby linking persistent viral infections with long-term disruptions of immune homeostasis. Emerging evidence indicates that CD57 expression denotes a state of terminal differentiation in both T and natural killer (NK) cell compartments, and is associated with cytotoxicity, altered cytokine secretion, and a pro-inflammatory phenotype. This review summarizes the phenotypic and functional characteristics of CD57+ lymphocytes, examines their association with CMV and other chronic viral infections, and explores their potential role in ageing and age-related diseases. Elucidating the biology of CD57+ lymphocytes in the context of chronic viral infections may provide novel insights into immune ageing and help identify potential targets for therapeutic strategies aimed at restoring immune balance in older adults.

26 August 2025 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
LSLucía Suanes-Cobos
Lucía Suanes-Cobos
IAIrene Aguilera-Ventura
Irene Aguilera-Ventura
MTMiguel Torres-Ramos
Miguel Torres-Ramos
ASAlejandra Serrano-Yubero
Alejandra Serrano-Yubero
CFClaudia Moreno Fernández-Aliseda
Claudia Moreno Fernández-Aliseda
MCMarco Antonio Calzado Canale
Marco Antonio Calzado Canale
Posttranslational modifications, such as ubiquitination and phosphorylation, play pivotal roles in regulating protein stability in response to cellular stress. Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) and ubiquitin-specific peptidase 28 (USP28) are critical regulators of cell cycle progression, DNA damage response, and oncogenic signaling. However, their functional interplay remains largely unexplored. Here, we describe a novel bidirectional regulatory mechanism between DYRK2 and USP28 that integrates DNA damage response and ubiquitin-mediated protein degradation. We demonstrate that DYRK2 phosphorylates USP28, promoting its ubiquitination and proteasomal degradation in a kinase activity-independent manner, thereby contributing to the maintenance of oncogenic protein homeostasis. Conversely, USP28 functions as a deubiquitinase for DYRK2, stabilizing its protein levels and enhancing its kinase activity. Notably, we show that DYRK2 interacts and co-localizes with USP28, with the 521–541 DYRK2 region, particularly residue T525, playing a crucial role in USP28-mediated DYRK2 stabilization. Functionally, this reciprocal regulation modulates p53 signaling, influencing apoptotic responses to DNA damage. DYRK2-mediated phosphorylation of p53 at S46 is significantly reduced upon USP28 depletion, suggesting that USP28 facilitates DYRK2-dependent apoptosis. Additionally, our results highlight a complex regulatory axis involving USP28 and DYRK2, with implications for oncogenic cell death and genomic stability. Overall, our findings uncover a novel feedback loop in which DYRK2 and USP28 dynamically regulate each other to control proto-oncoprotein homeostasis and DNA damage signaling. This interplay offers potential therapeutic opportunities for targeting cancers with dysregulated ubiquitination and genomic instability.

1 November 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
ACAntonio Costa
Antonio Costa
FVFernando Vázquez
Fernando Vázquez
COConsuelo Ortega
Consuelo Ortega
SÁSilvia Fernández Álvarez
Silvia Fernández Álvarez
EGElena Gomez
Elena Gomez
MSManuel Santamaría
Manuel Santamaría